Janice M. Mehnert, MD, on Novel Quadruplet in Unresectable Advanced Melanoma

Posted: Wednesday, June 18, 2025

Janice M. Mehnert, MD, of Perlmutter Cancer Center of NYU Langone Health/NYU Grossman School of Medicine, presents findings from an ongoing phase II study investigating the interleukin-6 receptor–blocking antibody sarilumab in combination with ipilimumab, nivolumab, and relatlimab in patients with unresectable stage III or IV melanoma.

---